Related Experiment Video
Updated: Mar 13, 2026
06:29
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
31.3K
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
C Wehling1, O Amon2, M Bommer3
1Institute of Immunology, University of Heidelberg, Heidelberg, Germany.
Clinical and Experimental Immunology
|October 27, 2016
Summary
Eculizumab effectively inhibits complement in atypical haemolytic uraemic syndrome (aHUS) but requires monitoring for optimal use in C3 glomerulopathies (C3G) and renal graft rejection. Drug accumulation and loss via urine highlight the need for tailored therapy.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Eculizumab, a complement inhibitor, is used for various complement-mediated renal disorders by blocking C5 cleavage.
- Complement-mediated inflammation contributes to cell damage in conditions like atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathies (C3G), and antibody-mediated renal graft rejection (AMR).
- Understanding complement activation pathways and eculizumab efficacy is crucial for optimizing treatment.
Purpose of the Study:
- To explore complement activation biomarkers during eculizumab treatment in patients with aHUS, C3G, and AMR.
- To assess the benefit of therapeutic drug monitoring for eculizumab in these renal disorders.
- To investigate eculizumab pharmacokinetics, including drug accumulation and urinary loss.
Main Methods:
- Analysis of complement activation biomarkers (CH50, APH50, C3, C3d, C5a, sC5b-9) in 23 patients across 12 German hospitals.
- Measurement of serum eculizumab concentrations using a newly developed ELISA.
- Correlation of biomarker levels and eculizumab concentrations with clinical outcomes and patient characteristics (e.g., age, proteinuria).
Main Results:
- Eculizumab treatment led to significant reductions in complement activation markers (CH50, APH50, C3d, sC5b-9) in aHUS patients.
- C3G patients showed ongoing complement activation at the C3 level (increased C3d, low C3) despite eculizumab therapy.
- Drug accumulation was observed, particularly in pediatric patients, and urinary eculizumab loss correlated with proteinuria.
Conclusions:
- Comprehensive complement analysis and therapeutic drug monitoring are essential for tailoring eculizumab therapy to specific renal disorders.
- Eculizumab efficacy varies, with clear inhibition in aHUS but less complete control in C3G, necessitating individualized treatment strategies.
- The observed drug accumulation and urinary loss underscore the need for patient-specific dosing to ensure optimal therapeutic outcomes.
Related Concept Videos
01:17Factors Affecting Renal Clearance: Renal Impairment
537
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
537
01:28Chronic Kidney Disease III: Interprofessional Care
570
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
570
01:26Nephrotic Syndrome II : Assessment and Medical Management
293
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
293
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
441
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
441
01:30Continuous Renal Replacement Therapy
1.6K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.6K
01:24Serum Studies: Renal Function Tests
564
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
564